Sanguinarine protects against ovariectomy‑induced osteoporosis in mice

Ma,Yan; Chu,Junjie; Ma,Jianjun; Ning,Lei; Zhou,Ke; Fang,Xiangqian

doi:10.3892/mmr.2017.6574

Sanguinarine protects against ovariectomy‑induced osteoporosis in mice

Authors:
- Yan Ma
- Junjie Chu
- Jianjun Ma
- Lei Ning
- Ke Zhou
- Xiangqian Fang
View Affiliations

Affiliations: Department of Orthopedic Surgery, Sir Run Run Shaw Institute of Clinical Medicine, Sir Run Run Shaw Hospital, Medical College of Zhejiang University, Hangzhou, Zhejiang 310016, P.R. China, Department of Head and Neck Surgery, Sir Run Run Shaw Institute of Clinical Medicine, Sir Run Run Shaw Hospital, Medical College of Zhejiang University, Hangzhou, Zhejiang 310016, P.R. China
Published online on: May 11, 2017 https://doi.org/10.3892/mmr.2017.6574
Pages: 288-294
Copyright: © Ma et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Natural compounds are alternative agents that have therapeutic potential for preventing and treating osteoporosis. Traditionally, sanguinarine has been used clinically due to its diverse biological properties, including antimicrobial, anti‑inflammatory and anticancer effects. Recently, for the first time, it was reported that sanguinarine inhibits osteoclast differentiation and bone resorption by suppressing the tumor necrosis factor ligand superfamily member 11‑induced nuclear factor‑κB and extracellular signal‑regulated kinase signaling pathways in vitro. Therefore, the present study further investigated the pharmacological effect of sanguinarine on osteoporosis in vivo. Micro‑computed tomography and histomorphometry analysis demonstrated that sanguinarine, at low and high concentrations, prevents ovariectomy (OVX)‑induced bone loss. In addition, further investigation of the cellular response in vivo revealed that sanguinarine inhibited osteoclastic bone resorption and promoted osteoblastic bone formation in a dose‑dependent manner. Therefore, the present study demonstrated that sanguinarine protected mice from OVX‑induced osteoporosis by modulating bone remodeling, indicating that sanguinarine may have potential in the treatment of osteoporosis.

View Figures

View References

1	Sipos W, Pietschmann P, Rauner M, Kerschan-Schindl K and Patsch J: Pathophysiology of osteoporosis. Wien Med Wochenschr. 159:230–234. 2009. View Article : Google Scholar : PubMed/NCBI
2	Weitzmann MN and Pacifici R: Estrogen deficiency and bone loss: An inflammatory tale. J Clin Invest. 116:1186–1194. 2006. View Article : Google Scholar : PubMed/NCBI
3	Rachner TD, Khosla S and Hofbauer LC: Osteoporosis: Now and the future. Lancet. 377:1276–1287. 2011. View Article : Google Scholar : PubMed/NCBI
4	Zhai YK, Pan YL, Niu YB, Li CR, Wu XL, Fan WT, Lu TL, Mei QB and Xian CJ: The importance of the prenyl group in the activities of osthole in enhancing bone formation and inhibiting bone resorption in vitro. Int J Endocrinol. 2014:9219542014. View Article : Google Scholar : PubMed/NCBI
5	Yogesh HS, Chandrashekhar VM, Katti HR, Ganapaty S, Raghavendra HL, Gowda GK and Goplakhrishna B: Anti-osteoporotic activity of aqueous-methanol extract of Berberis aristata in ovariectomized rats. J Ethnopharmacol. 134:334–338. 2011. View Article : Google Scholar : PubMed/NCBI
6	Lee WS, Lee EG, Sung MS and Yoo WH: Kaempferol inhibits IL-1β-stimulated, RANKL-mediated osteoclastogenesis via downregulation of MAPKs, c-Fos, and NFATc1. Inflammation. 37:1221–1230. 2014. View Article : Google Scholar : PubMed/NCBI
7	Tyagi AM, Srivastava K, Singh AK, Kumar A, Changkija B, Pandey R, Lahiri S, Nagar GK, Yadav DK, Maurya R, et al: Formononetin reverses established osteopenia in adult ovariectomized rats. Menopause. 19:856–863. 2012. View Article : Google Scholar : PubMed/NCBI
8	Liu X, Qu X, Wu C, Zhai Z, Tian B, Li H, Ouyang Z, Xu X, Wang W, Fan Q, et al: The effect of enoxacin on osteoclastogenesis and reduction of titanium particle-induced osteolysis via suppression of JNK signaling pathway. Biomaterials. 35:5721–5730. 2014. View Article : Google Scholar : PubMed/NCBI
9	Ouyang Z, Zhai Z, Li H, Liu X, Qu X, Li X, Fan Q, Tang T, Qin A and Dai K: Hypericin suppresses osteoclast formation and wear particle-induced osteolysis via modulating ERK signalling pathway. Biochem Pharmacol. 90:276–287. 2014. View Article : Google Scholar : PubMed/NCBI
10	Li H, Zhai Z, Liu G, Tang T, Lin Z, Zheng M, Qin A and Dai K: Sanguinarine inhibits osteoclast formation and bone resorption via suppressing RANKL-induced activation of NF-κB and ERK signaling pathways. Biochem Biophys Res Commun. 430:951–956. 2013. View Article : Google Scholar : PubMed/NCBI
11	Qu X, Zhai Z, Liu X, Li H, Ouyang Z, Wu C, Liu G, Fan Q, Tang T, Qin A and Dai K: Dioscin inhibits osteoclast differentiation and bone resorption though down-regulating the Akt signaling cascades. Biochem Biophys Res Commun. 443:658–665. 2014. View Article : Google Scholar : PubMed/NCBI
12	Mackraj I, Govender T and Gathiram P: Sanguinarine. Cardiovasc Ther. 26:75–83. 2008.PubMed/NCBI
13	American Psychological Association: Guidelines for Ethical Conduct in the Care and Use of Nonhuman Animals in Research. Washington, DC: American Psychological Association; 2012, http://www.apa.org/science/leadership/care/guidelines.aspx
14	Thompson DD, Simmons HA, Pirie CM and Ke HZ: FDA Guidelines and animal models for osteoporosis. Bone. 17:125S–133S. 1995. View Article : Google Scholar : PubMed/NCBI
15	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(−Delta Delta C(T)) Method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
16	Bouxsein ML, Boyd SK, Christiansen BA, Guldberg RE, Jepsen KJ and Muller R: Guidelines for assessment of bone microstructure in rodents using micro-computed tomography. J Bone Miner Res. 25:1468–1486. 2010. View Article : Google Scholar : PubMed/NCBI
17	Das S and Crockett JC: Osteoporosis-a current view of pharmacological prevention and treatment. Drug Des Devel Ther. 7:435–448. 2013.PubMed/NCBI
18	Buck DW III and Dumanian GA: Bone biology and physiology: Part I. The fundamentals. Plast Reconstr Surg. 129:1314–1320. 2012. View Article : Google Scholar : PubMed/NCBI
19	Odvina CV, Zerwekh JE, Rao DS, Maalouf N, Gottschalk FA and Pak CY: Severely suppressed bone turnover: A potential complication of alendronate therapy. J Clin Endocrinol Metab. 90:1294–1301. 2005. View Article : Google Scholar : PubMed/NCBI
20	Zaidi M and Iqbal J: Translational medicine: Double protection for weakened bones. Nature. 485:47–48. 2012. View Article : Google Scholar : PubMed/NCBI
21	Li YF, Zhou CC, Li JH, Luo E, Zhu SS, Feng G and Hu J: The effects of combined human parathyroid hormone (1–34) and zoledronic acid treatment on fracture healing in osteoporotic rats. Osteoporos Int. 23:1463–1474. 2012. View Article : Google Scholar : PubMed/NCBI
22	Bonnelye E, Chabadel A, Saltel F and Jurdic P: Dual effect of strontium ranelate: Stimulation of osteoblast differentiation and inhibition of osteoclast formation and resorption in vitro. Bone. 42:129–138. 2008. View Article : Google Scholar : PubMed/NCBI
23	Zhu LL, Blair H, Cao J, Yuen T, Latif R, Guo L, Tourkova IL, Li J, Davies TF, Sun L, et al: Blocking antibody to the β-subunit of FSH prevents bone loss by inhibiting bone resorption and stimulating bone synthesis. Proc Natl Acad Sci USA. 109:14574–14579. 2012. View Article : Google Scholar : PubMed/NCBI
24	Smoum R, Bar A, Tan B, Milman G, Attar-Namdar M, Ofek O, Stuart JM, Bajayo A, Tam J, Kram V, et al: Oleoyl serine, an endogenous N-acyl amide, modulates bone remodeling and mass. Proc Natl Acad Sci USA. 107:17710–17715. 2010. View Article : Google Scholar : PubMed/NCBI
25	Hayashi M, Nakashima T, Taniguchi M, Kodama T, Kumanogoh A and Takayanagi H: Osteoprotection by semaphorin 3A. Nature. 485:69–74. 2012. View Article : Google Scholar : PubMed/NCBI